|
Volume
24 Number 11
15 June 2022
|
|
Home
>
Publications
>
Current
Neuro-Oncology >
Volume
24, Year 2022 >
Number 11, 15 June
|
|
|
|
|
|
Reiner
AS, Lobaugh SM, Gonen S, Diamond EL, Panageas KS.
A
Population-Based Study of Treatment and Survival in Older Glioma
Patients.
JNCI
Cancer Spectr. 2022 Feb 9, 2022 Feb;6(1):pkac010⍈.
doi: 10.1093/jncics/pkac010⍈.
PMID: 35699501⍈.
Retrospective analysis. ⍈
|
|
|
|
Galanis
E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro
A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU,
Campian J, Giannini C, Buckner JC, Wen PY.
Phase
I/randomized phase II trial of TRC105 plus bevacizumab versus
bevacizumab in recurrent glioblastoma: North Central Cancer
Treatment Group N1174 (Alliance).
Neurooncol
Adv. 2022 Apr 4, 2022 Jan-Dec;4(1):vdac041⍈.
doi: 10.1093/noajnl/vdac041⍈.
PMID: 35664553⍈.
Phase1-2 clinical trial. ⍈
|
|
|
|
Grogan
PT, Deming DA, Helgager J, Ruszkiewicz T, Baskaya MK, Howard SP,
Robins HI.
Entrectinib
demonstrates prolonged efficacy in an adult case of
radiation-refractory NTRK
fusion
glioblastoma.
Neurooncol
Adv. 2022 Apr 13, 2022 Jan-Dec;4(1):vdac046⍈.
doi: 10.1093/noajnl/vdac046⍈.
PMID: 35673607⍈.
Case report. ⍈
|
|
|
|
Sangrador-Deitos
MV, Villanueva-Castro E, Marian-Magaña R,
Rodríguez-Hernández LA, Guinto-Nishimura GY,
Gómez-Amador JL, Corona-Vázquez T, Wegman-Ostorozky
T, Mejia S.
Carboplatin
Plus Vincristine as an Alternative Chemotherapeutic Scheme in
Patients With Glioblastoma.
Cureus.
2022 Apr 25;14(4):e24467⍈.
doi: 10.7759/cureus.24467⍈.
PMID: 35637821⍈.
Retrospective analysis. ⍈
|
|
|
|
Lin
MS, Lee CH, Chen SY, Shen CC.
Collision
brain tumor with atypical meningioma and glioblastoma: Case
report.
Int
J Surg Case Rep. 2022 May 4, 2022 May;94:107137⍈.
doi: 10.1016/j.ijscr.2022.107137⍈.
PMID: 35658305⍈.
Case report. ⍈
|
|
|
|
Seliger
C, Nürnberg C, Wick W, Wick A.
Lung
toxicity of lomustine in the treatment of progressive
gliomas.
Neurooncol
Adv. 2022 May 10, 2022 Jan-Dec;4(1):vdac068⍈.
doi: 10.1093/noajnl/vdac068⍈.
PMID: 35664555⍈.
Retrospective analysis. ⍈
|
|
|
*
|
Pauletto
G, Nilo A, Lettieri C, Verriello L, Tomasino B, Gigli GL, Skrap M,
Ius T.
Pre-
and Post-surgical Poor Seizure Control as Hallmark of Malignant
Progression in Patients With Glioma?
Front
Neurol. 2022 May 16;13:890857⍈.
doi: 10.3389/fneur.2022.890857⍈.
PMID: 35651351⍈.
Retrospective analysis. ⍈
|
|
|
*
|
Chi
X, Wang Y, Li C, Huang X, Gao H, Zhang Y, Ji N.
Resection
of Noncontrast-Enhancing Regions Deteriorated the
Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating
Glioblastoma.
Front
Oncol. 2022 May 18;12:877190⍈.
doi: 10.3389/fonc.2022.877190⍈.
PMID: 35664765⍈.
Phase 1 clinical trial. ⍈
|
|
|
*
|
Liu
CA, Harn HJ, Chen KP, Lee JH, Lin SZ, Chiu TL.
Targeting
the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy
to Butylidenephthalide in a Recurrent GBM.
J
Oncol. 2022 May 18;2022:3236058⍈.
doi: 10.1155/2022/3236058⍈.
PMID: 35646111⍈.
Case report. ⍈
|
|
|
|
Teng
C, Zhu Y, Li Y, Dai L, Pan Z, Wanggou S, Li X.
Recurrence-
and Malignant Progression-Associated Biomarkers in Low-Grade
Gliomas and Their Roles in Immunotherapy.
Front
Immunol. 2022 May 23;13:899710⍈.
doi: 10.3389/fimmu.2022.899710⍈.
PMID: 35677036⍈.
Prediction tool. ⍈
|
|
|
*
|
Ustjanzew
A, Sencio V, Trottein F, Faber J, Sandhoff R, Paret C.
Interaction
between Bacteria and the Immune System for Cancer Immunotherapy:
The α-GalCer Alliance.
Int
J Mol Sci. 2022 May 24;23(11):5896⍈.
doi: 10.3390/ijms23115896⍈.
PMID: 35682578⍈.
Laboratory investigation. ⍈
|
|
|
|
de
la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D,
Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S,
Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed
H, Monga V.
Olutasidenib
(FT-2102) in patients with relapsed or refractory IDH1-mutant
glioma: a multicenter, open-label, phase 1b/2 trial.
Neuro
Oncol. 2022 May 25:noac139⍈.
Doi: 10.1093/neuonc/noac139⍈.
PMID: 35639513⍈.
Phase 1b/2 clinical trial. ⍈
|
|
|
|
Klingenschmid
J, Krigers A, Kerschbaumer J, Thomé C, Pinggera D,
Freyschlag CF.
Surgical
Management of Malignant Glioma in the Elderly.
Front
Oncol. 2022 May 26;12:900382⍈.
doi: 10.3389/fonc.2022.900382⍈.
PMID: 35692808⍈.
Retrospective analysis. ⍈
|
|
|
|
Weiss
Lucas C, Faymonville AM, Loução R, Schroeter C,
Nettekoven C, Oros-Peusquens AM, Langen KJ, Shah NJ, Stoffels G,
Neuschmelting V, Blau T, Neuschmelting H, Hellmich M, Kocher M,
Grefkes C, Goldbrunner R.
Surgery
of Motor Eloquent Glioblastoma Guided by TMS-Informed
Tractography: Driving Resection Completeness Towards Prolonged
Survival.
Front
Oncol. 2022 May 27;12:874631⍈.
doi: 10.3389/fonc.2022.874631⍈.
PMID: 35692752⍈.
Prospective study. ⍈
|
|
|
|
Oberheim-Bush
NA, Shi W, McDermott MW, Grote A, Stindl J, Lustgarten L.
The
safety profile of Tumor Treating Fields (TTFields) therapy in
glioblastoma patients with ventriculoperitoneal shunts.
J
Neurooncol. 2022 May 31⍈.
doi: 10.1007/s11060-022-04033-4⍈.
PMID: 35639236⍈.
Retrospective analysis; ⍈
|
|
|
|
Varn
FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P,
Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV,
Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim
H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S,
Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D,
Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw
M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME,
Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM,
Noushmehr H, Iavarone A, Verhaak RGW; GLASS Consortium.
Glioma
progression is shaped by genetic evolution and microenvironment
interactions.
Cell.
2022 May 31, 2022 Jun 9;185(12):2184-2199.e16⍈.
doi: 10.1016/j.cell.2022.04.038⍈.
PMID: 35649412⍈.
Laboratory investigation; ⍈
|
|
|
|
Villani
V, Prosperini L, Lecce M, Tanzilli A, Farneti A, Benincasa D,
Telera S, Marucci L, Piludu F, Pace A.
Recurrent
glioblastoma: which treatment? A real-world study from the
Neuro-oncology Unit "Regina Elena" National Cancer
Institute.
Neurol
Sci. 2022 May 31⍈.
doi: 10.1007/s10072-022-06172-y⍈.
PMID: 35641731⍈.
Retrospective analysis; ⍈
|
|
|
|
Ruggi
A, Melchionda F, Sardi I, Pavone R, Meneghello L, Kitanovski L,
Zaletel LZ, Farace P, Zucchelli M, Scagnet M, Toni F, Righetto R,
Cianchetti M, Prete A, Greto D, Cammelli S, Morganti AG, Rombi
B.
Toxicity
and Clinical Results after Proton Therapy for Pediatric
Medulloblastoma: A Multi-Centric Retrospective Study.
Cancers
(Basel). 2022 Jun 1;14(11):2747⍈.
doi: 10.3390/cancers14112747⍈.
PMID: 35681727⍈.
Retrospective analysis. ⍈
|
|
|
|
Gupta
T, Pervez S, Dasgupta A, Chatterjee A, Epari S, Chinnaswamy G,
Jalali R.
Omission
of upfront craniospinal irradiation in patients with low-risk
WNT-pathway medulloblastoma is associated with unacceptably high
risk of neuraxial failure.
Clin
Cancer Res. 2022 Jun 2:clincanres.0758.2022-3-10 10:06:35.290⍈.
doi: 10.1158/1078-0432.CCR-22-0758? PMID: 35653134⍈.
Prospective study; ⍈
|
|
|
*
|
Duval
T, Lotterie JA, Lemarie A, Delmas C, Tensaouti F, Moyal EC,
Lubrano V.
Glioblastoma
Stem-like Cell Detection Using Perfusion and Diffusion
MRI.
Cancers
(Basel). 2022 Jun 4;14(11):2803⍈.
doi: 10.3390/cancers14112803⍈.
PMID: 35681782⍈.
Prospective study. ⍈
|
|
|
|
Cucchiara
F, Luci G, Giannini N, Giorgi FS, Orlandi P, Banchi M, Di Paolo A,
Pasqualetti F, Danesi R, Bocci G.
Association
of plasma levetiracetam concentration, MGMT methylation and sex
with survival of chemoradiotherapy-treated glioblastoma
patients.
Pharmacol
Res. 2022 Jun 6;181:106290⍈.
doi: 10.1016/j.phrs.2022.106290⍈.
PMID: 35680010⍈.
Retrospective analysis; ⍈
|
|
|
|
Saraf
A, Yock TI, Niemierko A, Oh KS, Curry WT, Butler WE,
Arrillaga-Romany I, Ebb DH, Tarbell NJ, MacDonald S, Loeffler JS,
Shih HA.
Long-term
outcomes and late toxicity of adult medulloblastoma treated with
combined modality therapy: a contemporary single-institution
experience.
Neuro
Oncol. 2022 Jun 7:noac126⍈.
doi: 10.1093/neuonc/noac126⍈.
PMID: 35671386⍈.
Retrospective analysis. ⍈
|
|
|
*
|
Ramos-Fresnedo
A, Domingo RA, Perez-Vega C, Pullen MW, Akinduro OO, Almeida JP,
Jentoft ME, Bendok BR, Chaichana KL, Trifiletti DM, Burns TC,
Porter AB, Kizilbash SH, Middlebrooks EH, Quiñones-Hinojosa
A, Sherman WJ.
The
early infiltrative phase of GBM hypothesis: are molecular
glioblastomas histological glioblastomas in the making? A
preliminary multicenter study.
J
Neurooncol. 2022 Jun 14⍈.
doi: 10.1007/s11060-022-04040-5⍈.
PMID: 35699848⍈.
Retrospective analysis; ⍈
|
|
|
|
Drljača
J, Popović A, Bulajić D, Stilinović N, Vidičević
Novaković S, Sekulić S, Milenković I, Ninković
S, Ljubković M, Čapo I.
Diazepam
diminishes temozolomide efficacy in the treatment of U87
glioblastoma cell line.
CNS
Neurosci Ther. 2022 Jun 15⍈.
doi: 10.1111/cns.13889⍈.
PMID: 35703405⍈.
Laboratory investigation. ⍈
|
|
|
|
Weller
J, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Schlegel
U, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Pietsch T,
Tzaridis T, Zeyen T, Borger V, Güresir E, Vatter H,
Herrlinger U, Schneider M.
Prognostic
impact of obesity in newly-diagnosed glioblastoma: a secondary
analysis of CeTeG/NOA-09 and GLARIUS.
J
Neurooncol. 2022 Jun 15⍈.
doi: 10.1007/s11060-022-04046-z⍈.
PMID: 35704157⍈.
Phase 2 and 3 clinical trials. ⍈
|
|
|
|
|
|
|
|
|
□□□
|
|
